3Singer D E,Albers G W,Dalen J E,et al.Antithrombotic Therapy in Atrial Fibrillation:the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy[J].Chest,2005,126(3 Suppl):429-456.
4Hirsh J,Dalen J E,Anderson D R,et al.Oral Anticoagulants:Mechanism of Action,Clinical Effectiveness,and Optimal Therapeuticrange[J].Chest,2001,119 (lSuppl):8-21.
5Hart R G,Benavent O,Mebride R,et al.Antit Hrombotic Therapy to Prevent Stroke in Patient Swith Atrial Fibrillation:A Meta-Analysis[J].Ann Intern Med,1999,131(7):492-501.
6Kirkwood T B.Calibration of Reference Thrombop Lastins and Standard-Isation of the Prothrombin Time Ratio[J].Thromb Haemost,1983,49(3):238-244.
7Psaty BM, Manolio TA, Kuller LH, et al. Incidence of and risk factors of atrial fibrillation in older adults. Circulation, 1997,96:2455- 2461.
8Gallus AS, Baker RI, Ockevford PA, et al. Consensus guidelines for warfarin therapy recommendation from the australasian society of thranrbosis and heamostasis. MJA,2000 ,172 :600.
